许小林
许小林
华盖资本 董事长、创始合伙人
许小林先生获北京大学经济学学士,北京大学EMBA,华盖资本创始合伙人、董事长。创立华盖资本之前,许小林先生曾任建银国际财富管理有限公司(建银国际产业基金)总经理、建银国际资产管理公司董事、投资总监,是建银国际私募股权板块创始人,成功筹建了国内第一只人民币医疗产业基金——建银国际医疗基金,管理建银系基金总规模达150亿。在此之前,还曾任长城证券并购部总经理等。许小林先生现还兼任“亮•中国”首届执行主席,中国创投委中华创投家同学会会长,“中国医疗健康投资50人论坛”发起人兼首届轮值主席,中国医药企业科学家投资家大会轮值主席。
许小林先生主导和参与了包括和美医疗、拜博口腔、科伦药业、步长制药、东阳光药业、鹭燕股份、康德莱、成大生物、康泰生物、博士眼镜、冠新软件、中和药业、复宏汉霖、正广兴、诺康达、赛诺威盛、宝岛妇产医院、海吉亚、德琪医药等近七十个大型境内外投资项。
并获“投2017清科投资界TOP100投资人”、“投中集团2016、2017年度中国医疗及健康服务产业最佳投资人Top10” “投中胡润2017年度中国最佳私募股权投资人Top50”。

Xiaolin Xu
Founding partner and chairman of Huagai Capital
Mr. Xu Xiaolin received a bachelor's degree in international economics at Peking University, EMBA at Peking University, founding partner and chairman of Huagai Capital. Prior to the creation of Huagai Capital, Mr. Xu Xiaolin was the general manager of CCB International Wealth Management Co., Ltd. (CCBI), director and chief investment officer of CCB International Asset Management Co., Ltd. and the founder of CCB International Medical Fund. Successfully set up the first domestic RMB fund of medical treatment industry -- medical fund CCB International Management Department of China Construction Bank, the total scale of the fund is up to 15 billion. Prior to that, also served as general manager of the merger of Great Wall Securities. Mr. Xu Xiaolin also serves as the first executive chairman of "Bright • China", the president of China Venture Capital and China Venture Capital Students Association, the sponsor and first rotating chairman of China's 50th Medical and Health Investment Forum, and a scientist investor of Chinese pharmaceutical enterprises, the rotating president of the conference.
Mr. Xu Xiaolin led and participated in nearly 70 large-scale domestic and foreign investment items, including Harmonicare Medica, Bybo Dental, Cologne Pharma, Buchang Pharma, East Sunshine Pharma, Lu Yan Pharma, Kant Lai, Chengda Biology, Kangtai Biology, Doctor, Great Soft, Zhonghe Pharma, Fuhong Hanlin, Zheng Guangxing, Nokangda, Sino Vision, Baodao Maternity Hospital, Hagia, Deqi Pharma , etc. And won " Top 100 Investors of China of Zero2IPO Group in 2017" , “ Top 10 Investors in China Medical and Health Care Industry of Chinaventure Group in 2016 and 2017"Top 50 Investors in China FT Excellence 2016 and 2017".